The multi-millicurie production of the SPECT radiopharmaceutical N,N,N′-trimethyl-N′-(2-hydroxy-3-methyl-5-[123I]i odobenzyl)-1,3-propanediamine ([123I]HIPDM) in high specific activity is described. Using no-carrier-added electrophilic iododeprotonation reactions and HPLC purification, [123I]HIPDM can be isolated in 70-76% radiochemical yield and specific activity >2000 Ci/mmol within an overall preparation time of 75 min. This methodology is readily adapted to the clinical setting, and eliminates the need for co-injection of macroscopic HIPDM in SPECT imaging procedures.
|Number of pages||5|
|Journal||International Journal of Radiation Applications and Instrumentation. Part|
|State||Published - 1990|